ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical practice"

  • Abstract Number: 2318 • 2016 ACR/ARHP Annual Meeting

    Real World Use of the Myositis Autoantibody Panel

    Jason Weiner1, Ryan Jessee2, Robert T. Keenan3, Michael Datto4 and Lisa Criscione-Schreiber5, 1Division of Rheumatology, Duke University, Durham, NC, 2Division of Internal Medicine, Duke University, Durham, NC, 3Rheumatology, Duke University, Durham, NC, 4Division of Pathology, Duke University, Durham, NC, 5Division of Rheumatology, Department of Medicine, Duke University, Durham, NC

    Background/Purpose: The identification of myositis specific and associated autoantibodies occurring in idiopathic inflammatory myopathies (IIMs) has improved classification and prognosis determinations.   With commercial availability, these…
  • Abstract Number: 2658 • 2016 ACR/ARHP Annual Meeting

    Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis

    Zulema Rosales Rosado1,2, Judit Font Urgelles1, Dalifer Freites Núñez1, Cynthia Milagros León Cárdenas1, Cristina Lajas Petisco1, Leticia Leon2, Luis Rodriguez Rodriguez2, Juan A Jover Jover1 and Lydia Abásolo Alcázar2, 1Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 2Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain

    Background/Purpose:  There is a high risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
  • Abstract Number: 2686 • 2016 ACR/ARHP Annual Meeting

    Objective Improvement in Fatigue Scores for Primary Sjögren’s Patients Receiving a Tailored Multidisciplinary Fatigue Intervention in a Generic Fatigue Clinic

    Katie Hackett1,2, Robert Forder3, Dennis W Lendrem4, Ben Hargreaves5, Victoria Strassheim1,3, Zoe Gotts3, Vincent Deary1,6, Wan-Fai Ng7,8 and Julia Newton1,3, 1CRESTA Fatigue Clinic, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 3Newcastle University, Newcastle upon Tyne, United Kingdom, 4Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 5Musculoskeletal Directorate, Newcastle upon Tyne NHS Foundation Trust, Newcastle, United Kingdom, 6School of Health Psychology, Northumbia University, Newcastle upon Tyne, United Kingdom, 7Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle University, Newcastle, England, 8Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Primary Sjögren’s syndrome (PSS) is an autoimmune disease which targets secretary glands resulting in dry eyes and mouth. Approximately 70% of PSS patients experience…
  • Abstract Number: 81 • 2016 ACR/ARHP Annual Meeting

    Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey

    Ara Dikranian1, James Galloway2, Joern Kekow3, Cristiano A.F Zerbini4, Maria de la Vega5, Gavin Lee6, Anna Maniccia7, Eustratios Bananis8, Dario Ponce de Leon9 and Allan Gibofsky10, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2King's College, and King´s College Hospital, London, United Kingdom, 3University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany, 4Centro Paulista de Investigação Clinica, São Paulo, Brazil, 5CEIM Investigaciones Médicas, Buenos Aires, Argentina, 6Hong Kong Sanatorium & Hospital, Hong Kong SAR, China, 7Pfizer Inc, New York, NY, 8Pfizer Inc, Collegeville, PA, 9Pfizer Inc, Lima, Peru, 10Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY

    Background/Purpose: RA is a chronic, debilitating condition for which there is no cure. To identify and better understand the perspectives of both healthcare providers (HCPs)…
  • Abstract Number: 3138 • 2016 ACR/ARHP Annual Meeting

    Sustained Improvement in Follow-up of Hypertension in Rheumatology Patients: Results of an Intervention Sustainability Assessment

    Edmond Ramly1,2, Daniel Panyard3, Diane Lauver4, Emmanuel Sampene5, Zhanhai Li5, Heather Johnson6, Patrick McBride6, Kristin Steffen Lewicki7 and Christie M. Bartels8, 1Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, 2Department of Medicine, University of Wisconsin-Madison, Madison, WI, 3Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, 4University of Wisconsin-Madison School of Nursing, Madison, WI, 5Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, 6Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 7Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 8Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Hypertension (HTN) is the most prevalent comorbid cardiovascular disease (CVD) risk factor among adults with rheumatic conditions.  However, we previously found that high blood…
  • Abstract Number: 90 • 2016 ACR/ARHP Annual Meeting

    Impacts of Anti-TNF Treatment on Improvement in Work Place and Household Productivity in Patients with Psoriatic Arthritis

    Omer Karadag1, Ediz Dalkilic2, Ahmet Mesut Onat3, Orhan Kucuksahin4, Timucin Kasifoglu5, Bunyamin Kisacik6, Omer Nuri Pamuk7, Neslihan Yilmaz8, Suleyman Serdar Koca9, Veli Yazisiz10, Pinar Talu Ocakci11, Mehmet Sayarlioglu12, Ender Terzioglu13, Sukran Erten14,15, Mustafa Ferhat Oksuz16 and Umut Kalyoncu1, 1Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 2Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, 3Department Of Internal Medicine, Division of Rheumatology, Gaziantep University, Gaziantep University,Division of Rheumatology, Gaziantep, Turkey, 4Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, 5Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, 6Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, 7Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, 8Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, 9Department of Rheumatology Faculty of Medicine Firat University, Elazig, Turkey, 10Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, 11Rheumatology, İzmir University Faculty of Medicine, izmir, Turkey, 12Rheumatology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey, 13Division of Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, 14Rheumatology, Ataturk Training and Research Hospital, Ankara, Turkey, 15Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, 16Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey

    Background/Purpose: Psoriatic arthritis (PsA) is a unique inflammatory arthritis that affects the skin, nails, and the joints. Most of the patients consider PsA to have…
  • Abstract Number: 3150 • 2016 ACR/ARHP Annual Meeting

    The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care

    Tuomas Rannio1, Juha Asikainen2, Pekka Hannonen2, Timo Yli-Kerttula3, Päivi Ekman4, Laura Kuusalo5, Laura Pirilä6, Markku Mali7, Marja Puurtinen-Vilkki7, Satu Kortelainen7, Johanna Paltta6, Kirsi Taimen7, Markku J. Kauppi8, Kari Laiho9, Satu Nyrhinen9, Heidi Mäkinen10, Pia Isomäki10, Terhi Uotila10, Kalle Aaltonen11, Hannu Kautiainen12 and Tuulikki Sokka-Isler1, 1Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, 2Jyvaskyla Central Hospital, Jyväskylä, Finland, 3Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, 4Satakunta Central Hospital, Rauma, Finland, 5Rheumatology, Turku University Central Hospital, Turku, Finland, 6Turku University Hospital, Turku, Finland, 7Turku University Central Hospital, Turku, Finland, 8Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, 9Päijät-Häme Central Hospital, Lahti, Finland, 10Tampere University Hospital, Tampere, Finland, 11Helsinki University, Helsinki, Finland, 12Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

      Background/Purpose: Methotrexate (MTX) is considered as the anchor disease modifying antirheumatic drug (DMARD) in treatment of rheumatoid arthritis (RA). However, there is no advice…
  • Abstract Number: 267 • 2016 ACR/ARHP Annual Meeting

    Diffuse Idiopathic Skeletal Hyperostosis: Can We Identify Different Clinicoradiological Patterns?

    Teresa Clavaguera1, Ramon Valls2 and Mari Carmen Rodriguez-Jimeno2, 1Unitat de Reumatologia, Hospital de Palamós, Girona, Spain, 2rheumatology, Hospital de Palamós, Palamós, Spain

    Background/Purpose:  Diffuse Idiopathic Skeletal Hyperostosis (DISH) was described based on vertebral radiological signs (Resnick). Subsequently, Utsinger presented other criteria that add extraspinal involvement that allowed…
  • Abstract Number: 3211 • 2016 ACR/ARHP Annual Meeting

    Early Radiological Progression in Rheumatoid Arthritis Leads to More Long-Term Joint Damage in Daily Clinical Practice; Six Year Radiological Outcomes of a Strict Treat-to-Target Cohort in the Netherlands

    Letty G.A. Versteeg1, Laura M.M. Steunebrink1, Ina H. Kuper1, Harald E. Vonkeman2, Peter M. ten Klooster3, Arie E. van der Bijl4 and Mart A.F.J. van de Laar5, 1Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 2koningsplein, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 3Pcgr, University of Twente, Enschede, Netherlands, 4Isala Klinieken, Zwolle, Netherlands, 5Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente and University Twente, Enschede, Netherlands

    Background/Purpose: Implementation of treat-to-target (T2T) in Rheumatoid Arthritis (RA) leads to limited radiological damage during follow-up of 3 years. Questions are whether these results are…
  • Abstract Number: 547 • 2016 ACR/ARHP Annual Meeting

    Concordance Between Ultrasound Joint Synovitis and Clinical Joint Assessments By Patients or Physicians in Rheumatoid Arthritis

    Ayako Hirata1, Takehisa Ogura1, Sayaka Takenaka1, Hideki Ito2, Yuki Fujisawa1, Kennosuke Mizushina1, Munetsugu Imamura1, Norihide Hayashi2 and Hideto Kameda1, 1Department of Rheumatology, Toho University Ohashi Medical Center, Tokyo, Japan, 2Toho University Ohashi Medical Center, Tokyo, Japan

    Background/Purpose: Ultrasonography (US) has been prevalently used as a valid and objective modality for joint examination in patients with rheumatoid arthritis (RA). This study aimed…
  • Abstract Number: 592 • 2016 ACR/ARHP Annual Meeting

    Impact of Adherence to Tumor Necrosis Factor Inhibitors on Radiographic Outcomes in US Veterans with Rheumatoid Arthritis

    Grant W. Cannon1, Alan R. Erickson2, Chia-Chen Teng3, Tina Huynh3, Sharon Austin4, Bradley S. Stolshek5, Alex Mutebi6, David Collier5, Sally W. Wade7 and Brian Sauer3, 1Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 4VAMC, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 5Amgen, Thousand Oaks, CA, 6Global Health Economics, Amgen, Thousand Oaks, CA, 7Wade Outcomes Research and Consulting, Salt Lake City, UT

    Background/Purpose:   Tumor necrosis factor inhibitors (TNFi) are effective therapy for rheumatoid arthritis (RA) and have been shown to reduce progression of joint structural damage…
  • Abstract Number: 705 • 2016 ACR/ARHP Annual Meeting

    Is a Positive Family History of Spondyloarthritis of Value in Patients with Chronic Back Pain? Results from Two Large Early Back Pain Cohorts

    Zineb Ez-Zaitouni1, Laure Gossec2, Inger Jorid Berg3, Robert Landewé4, Maikel van Oosterhout5, Mariagrazia Lorenzin6, Maxime Dougados7, Désirée van der Heijde8 and Floris van Gaalen1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Amsterdam Medical Center, Amsterdam, Netherlands, 5Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 6Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy, 7Paris-Descartes University, Paris, France, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: To assess whether presence of spondyloarthritis (SpA) manifestations in first- and second-degree relatives of patients with chronic back pain (CBP) is associated with higher…
  • Abstract Number: 729 • 2016 ACR/ARHP Annual Meeting

    Does the Presence of Multiple Spondyloarthritis-Features in Patients with Chronic Back Pain Always Lead to Diagnosis of Axial Spondyloarthritis?

    Zineb Ez-Zaitouni1, Pauline Bakker1, Miranda van Lunteren1, Inger Jorid Berg2, Robert Landewé3, Maikel van Oosterhout4, Mariagrazia Lorenzin5, Désirée van der Heijde1 and Floris van Gaalen1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Rheumatology, Academic Medical Center, Amsterdam, Netherlands, 4Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 5Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy

    Background/Purpose: The number of clinical spondyloarthritis (SpA)-features plays an important role in the Assessment of SpondyloArthritis international Society (ASAS) modified Berlin algorithm for the diagnostic…
  • Abstract Number: 906 • 2016 ACR/ARHP Annual Meeting

    Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice

    Luis Rodriguez Rodriguez1, Leticia Leon2, Inmaculada Morado1, Zulema Rosales Rosado2, Cristina Vadillo Font1, Dalifer Freites Núñez1, Pilar Macarrón1, Benjamín Fernández-Gutiérrez3, Juan A Jover Jover2 and Lydia Abásolo Alcázar2, 1Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 2Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 3Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain

    Background/Purpose: Several Clinical trials indicate that Methotrexate (MTX) could be considered as a feasible option in addition to corticosteroids for patients with GCA, but there…
  • Abstract Number: 2107 • 2015 ACR/ARHP Annual Meeting

    Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.

    Grant W. Cannon1, Chia-Chen Teng2, Ted R. Mikuls3, Jeffrey R. Curtis4, Derek Tang5, Bradley S. Stolshek5 and Brian Sauer6, 1Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, 3Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 4University of Alabama at Birmingham, Birmingham, AL, 5Amgen, Inc., Thousand Oaks, CA, 6Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

    Background/Purpose:   Combination therapy with methotrexate (MTX), sulfasalazine (SUL), and hydroxychloroquine (HCQ) [triple therapy] is an effective treatment for rheumatoid arthritis (RA).   Randomized controlled trials…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology